pharmaceutical investing Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma 23 July
pharmaceutical investing Allergan Aesthetics receives approval for Boey® , for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients 17 July
pharmaceutical investing SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development 14 July
